Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer.

Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer. Immunol Res. 2020 Jan 03;: Authors: Song IH, Kim YA, Lee H, Park HS, Park IA, Sim CK, Lee MS, Gong G, Lee HJ Abstract The expression of major histocompatibility complex class I (MHC I) in tumor cells is regulated by interferon signaling, and it is an important factor in the efficacy of cytotoxic T cell-dependent immunotherapy. To determine the impact of immune cells in MHC I expression on tumor cells, we compared the expression of MHC I in tumor cells derived from primary breast cancers and patient-derived xenograft (PDX) models. MHC I and myxovirus resistance gene A (MxA) expression were analyzed using immunohistochemistry in 23 cases of tumor tissue and corresponding primary and secondary PDXs. The median H score of MHC I was 210 (0-300) in patient tumor tissues, 197.5 (0-300) in primary PDX tumors, and 157.5 (5-300) in secondary PDX tumors. Cases were divided into four groups based on the difference in MHC I expression between the patient tumor tissues and secondary PDXs. Eleven cases constituted the high MHC I group, four constituted the low MHC I group, six comprised the decreased MHC I group, and two comprised the increased MHC I group. MHC I and MxA expressions in each tumor were weakly correlated within patients' tumors, while strongly correlated within PDX models. Retained or altered expression of ...
Source: Cell Research - Category: Cytology Authors: Tags: Immunol Res Source Type: research